A Study of GFH925 in Combination With Cetuximab in Previously Untreated Advanced NSCLC Harboring KRAS G12C Mutation

Summary

This is a Phase Ib/II study. The objectives are to evaluate the safety/tolerability and efficacy of GFH925 in combination with Cetuximab in advanced KRAS G12C mutant NSCLC, to characterize pharmacokinetics (PK) of GFH925 in combination with Cetuximab in advanced KRAS G12C mutant NSCLC

Timeline

Start

2023-04-25

Primary completion

2025-04-30

Completion

2025-04-30

Publications

• Gregorc V, Majem M, Lo Russo G, Maio M, Salvagni S, Gutierrez-Calderon V, Gonzalez-Cao M, Sandiego Contreras S, Koumarianou A, Bearz A, Bernabe-Caro R, Viteri S, de Sanmamed MF, Zagouri F, Moran Bueno T, Lazzari C, Martinez-Recio S, Gimenez-Capitan A, Zhang Y, Shan Y, Zhu H, Zhao C, Shen H, Wang Y, Rosell R. Fulzerasib plus cetuximab in first-line KRASG12C-mutated non-small-cell lung cancer (KROCUS): a single-arm, multicentre, phase 1b/2 trial. Lancet Oncol. 2026 Apr;27(4):432-441. doi: 10.1016/S1470-2045(25)00764-8.

Drugs

Indications